These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 16409185

  • 1. Anasarca improved by extracorporeal ultrafiltration through an internal shunt in a case of severe haemophilia B with inhibitor and steroid-resistant nephrotic syndrome.
    Satomura A, Takahashi S, Fujita T, Matsumoto K, Shichino H, Mugishima H.
    Haemophilia; 2006 Jan; 12(1):103-5. PubMed ID: 16409185
    [Abstract] [Full Text] [Related]

  • 2. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K, Hirose S, Taguchi H, Miyoshi I.
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract] [Full Text] [Related]

  • 3. [Coagulation factor IX inhibitor in hemophilia B].
    Lutze G, Mittler U, Presser HJ, Urbahn H.
    Z Med Lab Diagn; 1990 Jun; 31(2):113-9. PubMed ID: 2343619
    [Abstract] [Full Text] [Related]

  • 4. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R.
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
    Leissinger CA, Becton DL, Ewing NP, Valentino LA.
    Haemophilia; 2007 May; 13(3):249-55. PubMed ID: 17498073
    [Abstract] [Full Text] [Related]

  • 6. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M, Shirahata A.
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [Abstract] [Full Text] [Related]

  • 7. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD, Association of Hemophilia Clinic Directors of Canada (AHCDC), Canadian Association of Nurses in Hemophilia Care (CANHC).
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [Abstract] [Full Text] [Related]

  • 8. Dose and response in haemophilia--optimization of factor replacement therapy.
    Srivastava A.
    Br J Haematol; 2004 Oct; 127(1):12-25. PubMed ID: 15384973
    [Abstract] [Full Text] [Related]

  • 9. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D.
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [Abstract] [Full Text] [Related]

  • 10. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
    Soto I, Vicente JM, Corte JR, Urgellés MF, Pinto CR.
    Haemophilia; 2004 Jul; 10(4):401-4. PubMed ID: 15230957
    [Abstract] [Full Text] [Related]

  • 11. [Analysis of F.IX-inhibitor bypassing activity contained in a commercial prothrombin complex concentrate (Proplex)].
    Sugimoto M, Fujimura Y, Okubo Y, Takahashi Y, Yoshioka A, Fukui H.
    Nihon Ketsueki Gakkai Zasshi; 1984 Aug; 47(5):1181-9. PubMed ID: 6516702
    [No Abstract] [Full Text] [Related]

  • 12. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA, Neufeld EJ, Bennett CM.
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [Abstract] [Full Text] [Related]

  • 13. Nephrotic syndrome associated with hypocomplementemia in a 4-year-old boy with hemophilia B.
    Constantinescu AR, Weiss LS, Saidi P, Eisele J, Ettinger LJ.
    J Pediatr Hematol Oncol; 1997 May; 19(4):345-7. PubMed ID: 9256835
    [Abstract] [Full Text] [Related]

  • 14. Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation.
    Sharathkumar A, Hardesty B, Greist A, Salter J, Kerlin B, Heiman M, Sulkin M, Shapiro A.
    Haemophilia; 2009 Jan; 15(1):91-100. PubMed ID: 18721150
    [Abstract] [Full Text] [Related]

  • 15. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
    Mizon P, Goudemand J, Jude B, Marey A.
    Ann Hematol; 1992 Jun; 64(6):309-11. PubMed ID: 1637888
    [Abstract] [Full Text] [Related]

  • 16. Postsurgical hemorrhage resulting from a drug-induced circulating anticoagulant: report of case.
    Nersasian RR, Rosner T, Gilmore W.
    J Oral Surg; 1980 Sep; 38(9):688-90. PubMed ID: 6967961
    [Abstract] [Full Text] [Related]

  • 17. Acquired factor IX deficiency in the nephrotic syndrome.
    Natelson EA, Lynch EC, Hettig RA, Alfrey CP.
    Ann Intern Med; 1970 Sep; 73(3):373-8. PubMed ID: 5455988
    [No Abstract] [Full Text] [Related]

  • 18. Factor IX deficiency in the nephrotic syndrome.
    Koshy MC, Kashgarian M, Boreyko C.
    Conn Med; 1975 Aug; 39(8):472-4. PubMed ID: 1183212
    [No Abstract] [Full Text] [Related]

  • 19. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J.
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [Abstract] [Full Text] [Related]

  • 20. [Rational application of blood purification therapy in edema of children with nephrotic syndrome].
    Shen Y.
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):500-2. PubMed ID: 25224053
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.